Fundz

Numab Therapeutics Appoints Rajesh Chopra as Chief Scientific Officer

PRIVATEOct 01, 2026
New to company · from Prologue Medicines“He joins Numab from Prologue Medicines, where he served as Chief Scientific Officer”

Position

Chief Scientific Officer

Company

Numab Therapeutics

Rajesh Chopra, M.D., PhD
BiotechnologyHealth CareTherapeutics

Description

Numab Therapeutics has appointed Rajesh Chopra, M.D., PhD, as Chief Scientific Officer. With nearly four decades of experience in oncology and immunology, Dr. Chopra will enhance the company's scientific leadership and advance its innovative pipeline.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Numab Therapeutics, and when

A new leader at Numab Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Numab Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Numab Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Numab Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Numab Therapeutics

About

Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Numab Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

David
Likely contact at this company
••••••••@••••••••

See David's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Numab Therapeutics's next move

Learn about Strategic plan

Numab Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.